Drug Profile
Hydromorphone intranasal - Impel Pharmaceuticals
Alternative Names: INP-101Latest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Impel NeuroPharma
- Developer Impel Pharmaceuticals
- Class Analgesics; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
- 03 Nov 2017 Chemical structure information added
- 30 Oct 2017 Discontinued - Clinical-Phase-Unknown for Pain in USA (Intranasal) (Impel Neuropharma pipeline, October 2017)